You are here

Development of novel broad-spectrum influenza A inhibitors

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI093035-01A1
Agency Tracking Number: R43AI093035
Amount: $445,261.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA10-050
Solicitation Year: 2011
Award Year: 2011
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
11189 Sorrento Valley Rd, Suite 104
United States
DUNS: 962535782
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (919) 559-3653
Business Contact
Phone: (919) 559-3653
Research Institution

DESCRIPTION (provided by applicant): The influenza A virus represents one of the greatest global human health risks. While vaccines provide significant protection from seasonal flu infections they still account for an estimated 36,000 deaths and 200,000 hospitalizations per year in the US alone. Furthermore, the inherent time involved in development, production and distribution of vaccines limits their potential efficacy against rapidly emerging outbreaks. Two classes of drugs have been approved for influenza prophylaxis and treatment. Alarmingly, the past decade has witnessed the emergence of drug resistant as well as novel 2009 pandemic (H1N1) and highly pathogenic (H5N1) strains of influenza A. Amantadine- resistance has become so widespread the amantadanes have become all but ineffective and some flu strains have already exhibited significant resistance to neuraminidase inhibitors. Optimally, as adopted for the treatment of other viral diseases, combination drug therapies would be used to provide the mosteffective prophylaxis and treatment and to inhibit the emergence of additional drug- resistances. Thus, there is an urgent need for new and more effective antiviral mono- and combination therapies. Here we provide an innovative approach to identify inhibitors of both amantadine-sensitive and -resistant forms of the M2 proton channel to provide novel broad-spectrum therapeutics. Using this approach we provide a platform for the identification of new inhibitory compounds acting at novel sites of a clinicallyvalidated influenza A target for the development of new mono- and combination antiviral drug therapies; a designated NIAID high priority area of interest. PUBLIC HEALTH RELEVANCE: Over the past decade the emergence of a number of drug-resistant and/or highly pathogenic variants of influenza have dramatically increased the potential impact of influenza infection. This proposal details an innovative approach to identify much needed novel inhibitors and potential therapeutics for the prevention and treatment of influenza A infection for mono and combination drug therapies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government